US 2026/0274993 A1Published application

Vh4-34 antigen-binding molecules

AssigneeHummingbird Bioscience Pte. Ltd.

InventorsShalini Paliwal, Dipti Thakkar, Wen Jie Chin, Warren Lee, Jacklyn Jie Ying Neo, Brendon Hanson, Konrad Paszkiewicz, Piers Ingram, Jerome Boyd-Kirkup, Adelene Sim

Life of this patent

Estimating the term…

Abstract

Provided herein are VH4-34 antigen binding molecules (e.g., VH4-34 antibodies). compositions comprising the same, and methods of use.

Claims39

Dependent claims

A VH4-34 antigen-binding molecule comprising:

(a)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
172;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
144:
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(b)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
142;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
144;
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(c)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
38;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
39;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
40, and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
46;
a LC-CDR2 having the amino acid sequence AAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
48;
or
(d)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
54;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
62;
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(e)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
6:
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
7;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
8;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
131;
a LC-CDR2 having the amino acid sequence LVS:
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
16;
or
(f)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
22;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
23;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
24;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
30;
a LC-CDR2 having the amino acid sequence YTS:
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
32;
or
(g)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
6,
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
7;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
8;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
162;
a LC-CDR2 having the amino acid sequence LVS:
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
16;
or
(h)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
152:
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
154:
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(i)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
185;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
144:
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(j)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
6;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
7:
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
8;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
14;
a LC-CDR2 having the amino acid sequence LVS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
16.

155 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/163,241Filed 8 Mar 2024
Priority: 9 Mar 2023
Published: 17 Sep 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
C07K 16/4208
Against immunoglobulins: against an idiotypic determinant on Ig
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/416
Vertebrate antigens: antigens related to auto-immune diseases; Preparations to induce self-tolerance

Family

Application63/451,053Us provisional application · filed 9 Mar 2023
US 2026/0274993 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

A VH4-34 antigen-binding molecule comprising:

(a)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
172;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
144:
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(b)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
142;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
144;
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(c)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
38;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
39;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
40, and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
46;
a LC-CDR2 having the amino acid sequence AAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
48;
or
(d)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
54;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
62;
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(e)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
6:
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
7;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
8;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
131;
a LC-CDR2 having the amino acid sequence LVS:
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
16;
or
(f)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
22;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
23;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
24;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
30;
a LC-CDR2 having the amino acid sequence YTS:
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
32;
or
(g)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
6,
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
7;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
8;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
162;
a LC-CDR2 having the amino acid sequence LVS:
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
16;
or
(h)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
152:
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
154:
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(i)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
185;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
55;
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
56;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
144:
a LC-CDR2 having the amino acid sequence YAS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
64;
or
(j)
(i) a heavy chain variable (VH) region comprising:
a HC-CDR1 having the amino acid sequence of SEQ ID NO:
6;
a HC-CDR2 having the amino acid sequence of SEQ ID NO:
7:
a HC-CDR3 having the amino acid sequence of SEQ ID NO:
8;
and
(ii) a light chain variable (VL) region comprising:
a LC-CDR1 having the amino acid sequence of SEQ ID NO:
14;
a LC-CDR2 having the amino acid sequence LVS;
a LC-CDR3 having the amino acid sequence of SEQ ID NO:
16.

155 more elements

Facts

Application

19/163,241Filed 8 Mar 2024

Priority

9 Mar 2023

Published

17 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
C07K 16/4208
Against immunoglobulins: against an idiotypic determinant on Ig
A61K 40/31
Characterised by the recombinant expression of specific molecules in the cells of the immune system: chimeric antigen receptors [CAR]
A61K 40/416
Vertebrate antigens: antigens related to auto-immune diseases; Preparations to induce self-tolerance